Spots Global Cancer Trial Database for 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

Official Title: 2006-32: Phase II Study of Rapidly Recycled High Dose DTPACE (HD-DTPACE) for Untreated or Previously Treated, High-Risk Multiple Myeloma (MM)

Study ID: NCT00577512

Conditions

Multiple Myeloma

Interventions

DTPACE

Study Description

Brief Summary: This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.

Detailed Description: This study has the following goals: * To find out how many subjects treated with high dose DTPACE (Dexamethasone, Thalidomide, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer. * In subjects achieving a response, to find out how long the response will last. * To learn more about the side effects of this treatment. Up to 75 subjects, male or female, age 18 and older, regardless of race or ethnicity, will participate in this study at the University of Arkansas for Medical Sciences (UAMS) only. The treatment in this study is divided into 3 parts * High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored. * High dose DTPACE and stem cell re-infusion. * Velcade, Thalidomide, Dexamethasone (sometimes known as VTD) Maintenance therapy.